Dry Powder Inhaler Formulations for Pulmonary NSAID Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for pulmonary delivery of NSAIDs, such as aspirin, face challenges in generating dry powders with appropriate particle size, density, and dispersibility, leading to inefficiencies and reduced drug dosages due to aggregation and the need for inert carriers, which compromise purity and bioavailability.
Innovation Solution
Development of respirable dry powders comprising NSAIDs like acetylsalicylic acid with varying particle sizes (0.5 μm to 30 μm) and a mass median aerodynamic diameter of 20 μm or less, optionally including pharmaceutically acceptable excipients like leucine, sodium citrate, or maltodextrin, to enhance dispersibility and bioavailability through a dry powder inhaler.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If dry powder formulations are used for pulmonary delivery of NSAIDs, then rapid onset and reduced side effects are achieved, but particle aggregation occurs and dispersibility is reduced
Solution Approach 1:
The patent uses lactose as an intermediary carrier particle to improve the dispersibility of NSAID particles. The lactose particles act as a mediator that prevents aggregation of the active drug particles, enabling better aerosolization and pulmonary delivery while maintaining the rapid onset advantage of dry powder formulations.
Solution Approach 2:
The invention creates composite dry powder formulations consisting of NSAID particles blended with lactose carrier particles. This composite material combines the therapeutic benefits of NSAIDs with the dispersibility advantages of lactose, resolving the contradiction between rapid onset and particle stability.
2Stability of the object's composition
If inert carriers like lactose are used to enable dosing of small respirable particles, then dispersibility is improved, but drug purity and active ingredient content are reduced
Solution Approach 1:
The patent optimizes the size parameters of both the NSAID particles and the lactose carrier particles. By controlling the particle size distribution and size ratio between drug and carrier, the formulation achieves effective dispersibility while minimizing the amount of inert carrier needed, thus maintaining high active drug content.
3Productivity
If smaller respirable dry particles are used to improve inhalation delivery, then drug delivery efficiency is enhanced, but particle aggregation increases and flowability decreases
Solution Approach 1:
The lactose carrier particles provide a counterbalancing effect to the aggregation tendency of small NSAID particles. The larger, more flowable lactose particles act as spacers that prevent small drug particles from aggregating, thereby maintaining both respirability and flowability in the dry powder formulation.
Data Source
AI summary
The subject technology relates generally to pulmonary delivery of NSAIDs, such as aspirin.